Pharma Stocks

Cipla reported total income from operations of ₹6,541 crore, down 2.8 per cent year-on-year (Y-o-Y) from ₹6,730 crore in the year-ago period

Hold existing investments if you have a long horizon; book partial profits if exposure exceeds 10 per cent

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period

Dr Reddy's net profit is expected to come at ₹1,035 crore, marking a moderate 34 per cent Y-o-Y decrease, on average, as against ₹1,587 crore in the Q4FY25

In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent

Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.

Cipla has received the US FDA's approval for generic Ventolin inhaler. Analysts see $100-million sales potential from the drug, which could aid US business outlook

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Sun Pharma shares fall 5 per cent amid Organon deal buzz and US tariff concerns. Tech charts show the stock has a 'bearish' outlook

Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.

Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

The company said decrease in revenue from operations during Q3FY26 is due to lower sales of PI and Artificial Sweeteners.

Analysts at Choice Broking expects Dr Reddy's Laboratories stock to gain up to 15.5%, and test ₹1,465 levels on the upside in the medium-term given the favourable structure on the weekly chart.

Divi's Laboratories reported a consolidated profit after tax (PAT) of ₹583 crore, marginally lower than ₹589 crore in the same period last year

Alembic Pharma shares today: Analysts at Motilal Oswal Financial Services (MOFSL) have retained their Neutral rating on Alembic Pharma, with a target price of ₹860 per share

Strong Q3 performance and a steady pipeline of new launches are expected to support Sun Pharma's growth outlook, with brokerages upgrading the stock

Aurobindo Pharma stock up on Friday: The government has imposed a Minimum Import Price fixed at ₹2,216/kg for Penicillin G and is expected to provide a significant benefit to the company.